Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Nov 12, 10:37 PMAlvotech reiterates 2026 outlook low end as supply ramps, IP risks loom
Index
-
Market Cap
1.64B
Enterprise Value
3.14B
Income
-249.21M
Sales
489.61M
Book/sh
-0.68
Cash/sh
0.16
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
1460
IPO
Nov 09, 2020
P/E
-
Forward P/E
17.03
PEG
-
P/S
3.34
P/B
-
P/C
26.61
P/FCF
-
EV/EBITDA
31.76
EV/Sales
6.40
Quick Ratio
0.94
Current Ratio
1.78
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-0.73
EPS next Y
0.25
EPS next Q
0.17
EPS this Y
14.76%
EPS next Y
388.67%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
91.85% -
EPS Y/Y TTM
-417.72%
Sales Y/Y TTM
-14.25%
EPS Q/Q
-1002.30%
Sales Q/Q
-2.06%
Insider Own
55.53%
Insider Trans
0.00%
Inst Own
11.92%
Inst Trans
8.10%
ROA
-16.48%
ROE
-
ROIC
-20.33%
Gross Margin
56.83%
Oper. Margin
11.51%
Profit Margin
-50.90%
SMA20
-11.74%
SMA50
-19.91%
SMA200
0.17%
Trades
Shs Outstand
390.43M
Shs Float
173.61M
52W High
6.53 -35.83%
52W Low
2.94 42.52%
Volatility
7.44% 5.57%
ATR (14)
0.31
RSI (14)
35.90
Beta
0.25
Rel Volume
0.00
Avg Volume
1.12M
Volume
0
Perf Week
-13.79%
Perf Month
-21.09%
Perf Quarter
7.99%
Perf Half Y
26.59%
Perf YTD
-18.32%
Perf Year
-24.09%
Perf 3Y
-53.55%
Perf 5Y
-57.68%
Perf 10Y
-
Prev Close
4.19
Price
4.19
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$7.56
Implied Upside
+80.4%
Analysts8incl. previous ratings
Rating Distribution6 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 10, 2026Initiated
JEF logoJJefferies
Buy$9+114.8%
Sep 16, 2026Upgrade
BCS logoBBarclays
Underweight → Overweight$8+90.9%
Aug 24, 2026Initiated
BAC logoBBofA Securities
Buy$7+67.1%
Aug 14, 2026Initiated
EVR logoEEvercore ISI
Outperform
Dec 09, 2025Initiated
BCS logoBBarclays
Underweight$5+19.3%
Nov 04, 2025Downgrade
DB logoDDeutsche Bank
Buy → Hold$8+90.9%
Oct 14, 2025Upgrade
MS logoMMorgan Stanley
Equal-Weight → Overweight$14+234.1%
Sep 23, 2025Upgrade
DB logoDDeutsche Bank
Hold → Buy$14+234.1%
Feb 14, 2025Initiated
UBS logoUUBS
Buy$18+329.6%
Jan 29, 2024Upgrade
BCS logoBBarclays
Equal Weight → Overweight$10 → $17+305.7%
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.
Founder & Executive ChairmanMr. Vilhelm Robert Wessman
Chief Executive OfficerMs. Lisa Graver
Chief Financial OfficerMs. Linda Jonsdottir
Chief Operating OfficerMr. Joseph E. McClellan
Chief Information OfficerMs. Neha Patel